menu
    • menu
    [{"orgOrder":0,"company":"Relaxera Pharmazeutische","sponsor":"CBL- Chemical and Biopharmaceutical Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human Relaxin-2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relaxera Pharmazeutische","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relaxera Pharmazeutische \/ CBL Patras","highestDevelopmentStatusID":"8","companyTruncated":"Relaxera Pharmazeutische \/ CBL Patras"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Relaxin-2 protein, human","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Relaxin-2 protein, human

    Menu

    Relaxin-2 protein, human

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tectonic Therapeutic

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Pres...

                            Details : TX45 is an investigational long-acting relaxin-Fc fusion molecule. It is being evaluated for the treatment of group 2 pulmonary hypertension secondary to heart failure with preserved ejection fraction.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Relaxera Pharmazeutische

                            Germany arrow
                            Luxepack
                            Not Confirmed

                            Relaxera Pharmazeutische

                            Germany arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : CBL- Chemical and Biopharmaceutical Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human Relaxin-2

                            Details : This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 16, 2020

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : CBL- Chemical and Biopharmaceutical Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth